Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Galectin Therapeutics Inc.

The latest update is out from Galectin Therapeutics ( ($GALT) ). On July 31, 2026, Galectin Therapeutics converted all outstanding principal and ac...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GALT	$3.45	+7.14%	329.87K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GALT	$3.45	+7.1%	329.87K
3
4
5
6

GALT

GALT

Get Galectin Therapeutics Inc. Data in Excel

Get Galectin Therapeutics Inc. Data in Excel